TICKERNERD
Menu
BMYBMYHealthcare · Drug Manufacturers - General

BMY Stock Forecast: Bristol Myers Squibb Co. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$67
+2.35% on the day

The 28 Wall Street analysts covering Bristol Myers Squibb Co. hold a median 12-month price target of $68 — +1.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$136.9B
Ticker Nerd rank
99 / 100
Median analyst target
$68
Analysts covering
28
Total return, dividends reinvested
1W
+5.0%
1M
+10.0%
YTD
+28.4%
1Y
+44.9%
From 52W high
−0.9%
From 52W low
+62.6%
$41
$68
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BMY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bristol Myers Squibb Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Volatility
100
Revisions
98
Issuance
93
Quality
92
Momentum
83
Growth
67
Accruals
65
Size
2

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (65): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BMY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BMY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$50$60$70$80Oct 25Jan 26Apr 26Jul 26BMYHigh $80Median $68Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says28 analysts
10 Buy17 Hold1 Sell
Low $40Median $68High $80

The green dot is the last close — the median target sits +1.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
5 Aug 2026Argus ResearchUpgradeBuy$75
3 Aug 2026CitigroupMaintainsNeutral$66 → $70
31 July 2026Cantor FitzgeraldMaintainsNeutral$54 → $59
31 July 2026GuggenheimMaintainsBuy$72 → $75
31 July 2026JP MorganMaintainsOverweight$67 → $73
31 July 2026RBC CapitalMaintainsSector Perform$60 → $64
31 July 2026Truist SecuritiesReiteratesBuy$65 → $70
31 July 2026Wells FargoMaintainsEqual-Weight$60 → $65
10 July 2026B of A SecuritiesMaintainsBuy$67 → $66
10 July 2026B of A SecuritiesMaintainsBuy—
6 July 2026Cantor FitzgeraldReiteratesNeutral$54
6 July 2026Cantor FitzgeraldReiteratesNeutral—
9 Apr 2026B of A SecuritiesMaintainsBuy—
8 Apr 2026Cantor FitzgeraldMaintainsNeutral—
8 Apr 2026GuggenheimReiteratesBuy—
17 Mar 2026HSBCMaintainsHold—
25 Feb 2026RBC CapitalInitiatesSector Perform—
23 Feb 2026Piper SandlerMaintainsOverweight—
20 Feb 2026BarclaysInitiatesOverweight—
6 Feb 2026CitigroupMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BMY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+10.1%
Analysts raising
24
Analysts cutting
0
Fundamentals

Bristol Myers Squibb Co. (BMY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
14.8×

Cheaper than 47% of US stocks

Price / sales
2.8×

Cheaper than 44% of US stocks

Price / book
6.1×

Cheaper than 18% of US stocks

EV / EBITDA
9.0×

Cheaper than 43% of US stocks

Growth & margins
Revenue growth (YoY)
5.7%

Higher than 41% of US stocks

Earnings growth (YoY)
153.2%

Higher than 88% of US stocks

Gross margin
71.3%

Higher than 84% of US stocks

Operating margin
34.4%

Higher than 89% of US stocks

Net margin
18.9%

Higher than 81% of US stocks

Returns & dividend
Return on equity
46.6%

Higher than 92% of US stocks

Return on assets
10.7%

Higher than 93% of US stocks

Dividend yield
3.8%

Higher than 75% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BMY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
BMYBristol Myers Squibb Co.$136.9B
99
PFEPfizer Inc.$159.6B
79
GILDGilead Sciences, Inc.$181.4B
92
AMGNAmgen, Inc.$236.8B
92
MRKMerck & Co., Inc.$378.6B
83
ABBVAbbVie, Inc.$468.1B
96
BIIBBiogen, Inc.$31.8B
73

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bristol Myers Squibb Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BMY news & analysis

Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?

Zacks Investment Research · 21 Aug 2026positive

Bristol Myers Squibb's legacy portfolio is facing generic pressure, but stronger Eliquis sales are prompting a brighter 2026 revenue outlook for the company, according to Zacks Investment Research.

Why it matters — A BMY watcher would care because stronger Eliquis sales could help offset the erosion of the company's legacy portfolio from generic competition, supporting its revenue outlook.

Here's Why Bristol Myers Squibb (BMY) is a Strong Momentum Stock

Zacks Investment Research · 21 Aug 2026positive

Zacks Investment Research highlights Bristol Myers Squibb as a strong momentum stock, noting that its Style Scores system helps investors identify top-rated stocks based on investing style. The article explains why investors should consider taking advantage of this tool.

Why it matters — BMY watchers would care because the piece signals that the stock is being recognized for strong momentum characteristics, which could inform how they view its current market positioning.

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

Zacks Investment Research · 19 Aug 2026positive

Zacks Investment Research highlights Bristol Myers Squibb as a strong value stock using its Zacks Style Scores feature, which helps investors identify stocks across value, growth, and momentum categories.

Why it matters — A positive value-stock designation from Zacks may draw attention to BMY from value-focused investors tracking the company.

AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?

Seeking Alpha · 19 Aug 2026neutral

Seeking Alpha examines AstraZeneca and Bristol-Myers Squibb as standalone investment options, noting that merger rumors have cooled. The article highlights that both companies hold leading positions in cancer and immune-mediated inflammatory diseases, with each having strengths and weaknesses in their drug portfolios relative to the other.

Why it matters — A BMY watcher would gain a comparative view of the company's competitive standing and portfolio against a major rival in key therapeutic markets.

FAQ

Frequently asked questions about BMY stock

What is the BMY stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Bristol Myers Squibb Co. have a median 12-month price target of $68, with estimates ranging from $40 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BMY stock a buy right now?

Of the 28 analysts covering Bristol Myers Squibb Co., 10 rate it a Buy, 17 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bristol Myers Squibb Co. 99 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BMY?

As at 22 Aug 2026, Bristol Myers Squibb Co. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will BMY stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +1.5% from the last close, and Ticker Nerd's factor model ranks Bristol Myers Squibb Co. 99 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BMY stock forecast for 2030?

No analyst covering Bristol Myers Squibb Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $80 over the next 12 months.

How has BMY stock performed over the past year?

Bristol Myers Squibb Co. returned +44.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bristol Myers Squibb Co. do?

Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, licensing, manufacturing, and commercializing medicines for serious diseases. Bristol-Myers Squibb Company’s portfolio spans oncology, hematology, immunology, cardiovascular disease, and neuroscience, with products that include small-molecule drugs, biologics, and CAR-T cell therapies.

What is the latest news on BMY?

The most recent item we track (Zacks Investment Research, 21 Aug 2026): "Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?". Bristol Myers Squibb's legacy portfolio is facing generic pressure, but stronger Eliquis sales are prompting a brighter 2026 revenue outlook for the company, according to Zacks Investment Research.

Company

About Bristol Myers Squibb Co.

Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, licensing, manufacturing, and commercializing medicines for serious diseases. Bristol-Myers Squibb Company’s portfolio spans oncology, hematology, immunology, cardiovascular disease, and neuroscience, with products that include small-molecule drugs, biologics, and CAR-T cell therapies. The company serves patients and healthcare providers worldwide through branded therapies and specialty medicines used in complex treatment settings. Bristol-Myers Squibb Company also supports ongoing research and development across multiple therapeutic areas, combining scientific expertise with large-scale manufacturing and distribution capabilities. Headquartered in Princeton, New Jersey, and founded in 1933, Bristol-Myers Squibb Company remains a major participant in the global pharmaceutical market, known for advancing treatments aimed at addressing high-need medical conditions.

CEO Dr. Christopher S. Boerner Ph.D. · 32,500 employees · United States · https://www.bms.com